durvalumab
Also known as MEDI4736, MEDI-4736, Imfinzi
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
Key facts
- Drug.type
- mab
- Drug.image
- Durvalumab PD-L1 5X8M.pdb.png
- Drug.caption
- Antigen-binding fragment of durvalumab (pale green) in complex with PD-L1 (pink). .
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- CD274
- Drug.tradename
- Imfinzi
- Drug.MedlinePlus
- a617030
- Drug.DailyMedID
- Durvalumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
~14 min read
Article
11 sectionsContents
- Medical uses
- History
- Clinical trials
- MYSTIC
- PACIFIC
- CASPIAN
- TOPAZ-1
- DUO-E
- AEGEAN
- WHO Confirmation of Falsified IMFINZI
- References
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
Durvalumab is an immune checkpoint inhibitor drug. It was approved in for medical use in the United States in May 2017, and in the European Union in September 2018.